NCT04227756View on ClinicalTrials.gov

Comparative Acute Effects of LSD, Psilocybin and Mescaline

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 19, 2020

Primary Completion Date

September 2, 2022

Study Completion Date

September 2, 2022

Conditions
Healthy
Interventions
DRUG

LSD

LSD 0.1 mg per os, single dose OR Psilocybin 20 mg per os, single dose OR Mescaline 300 mg per os, single dose OR Placebo

DRUG

Psilocybin

Psilocybin 20 mg per os, single dose

DRUG

Mescaline

Mescaline 300 mg or 500 mg per os, single dose

OTHER

Placebo

Placebo (Mannitol)

Trial Locations (1)

4031

University Hospital Basel, Clinical Trial Unit, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER

NCT04227756 - Comparative Acute Effects of LSD, Psilocybin and Mescaline | Biotech Hunter | Biotech Hunter